| 产品描述： | BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer |
| 靶点： |
IC50: 0.92 μM (AIMP2-DX2), IC50: >100 μM (AIMP2) |
| 体内研究： |
BC-DXI-843 (50 mg/kg; intraperitoneally administered; every other day for 15 days) demonstrates in vivo efficacy in a tumor xenograft mouse model (H460 cells). Animal Model: 7-week-old female BALB/cSLC-nu/nu mice bearing H460 cells xenograft Dosage: 50 mg/kg Administration: Intraperitoneally administered; every other day for 15 days Result: The embedded tumor volume gradually declined after BC-DXI-843administration, but no changes in body weight were observed. The weight of the excised tumors after sacrifice had decreased in mice. |
| 细胞实验： |
1. Aneesh Sivaraman, et al. Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy. J Med Chem. 2020 May 28;63(10):5139-5158. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.829 ml |
9.146 ml |
18.293 ml |
| 5 mM |
0.366 ml |
1.829 ml |
3.659 ml |
| 10 mM |
0.183 ml |
0.915 ml |
1.829 ml |
| 50 mM |
0.037 ml |
0.183 ml |
0.366 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京